Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients.
- Author:
Ozgur OZYILKAN
1
;
Ulku YALCINTAS
;
Sezgin BASKAN
Author Information
1. Bayindir Medical Centre, Division of Medical Oncology, Ankara.
- Publication Type:Original Article ; Clinical Trial ; Randomized Controlled Trial
- Keywords:
Imipenem-Cilastatin;
Sulbactam-Cefoperazone;
Amikacin;
Neutropenic fever
- MeSH:
Adolescence;
Adult;
Aged;
Aged, 80 and over;
Amikacin/therapeutic use;
Antibiotics, Combined/therapeutic use*;
Bacteremia/drug therapy;
Bacteremia/complications;
Cefoperazone/therapeutic use;
Cilastatin/therapeutic use;
Female;
Fever/drug therapy*;
Fever/complications;
Human;
Imipenem/therapeutic use;
Male;
Middle Age;
Neoplasms/drug therapy*;
Neoplasms/complications;
Neutropenia/drug therapy*;
Neutropenia/complications;
Prospective Studies;
Sulbactam/therapeutic use
- From:The Korean Journal of Internal Medicine
1999;14(2):15-19
- CountryRepublic of Korea
- Language:English
-
Abstract:
The treatment of infectious complications in cancer patients has evolved as a consequence of the developments in the chemotherapy of cancer patients. In this prospective, randomized study, we compared imipenem-cilastatin and sulbactam-cefoperazone with amikacin in the empiric therapy of febrile neutropenic (< 1000/mm3) patients with liquids and solid tumours. Of 30 evaluable episodes, 15 were treated with imipenem-cilastatin and 15 were treated with sulbactam-cefoperazone plus amikacin. 73% of episodes were culture-positive: gram-positive pathogens accounted for 62% of the isolates. Bacteremia was the most frequent site of infection. The initial clinical response rate for both regimens was 60% (p > 0.05). No major adverse effects occurred. This study demonstrated that imipenem-cilastatin monotherapy and combination therapy of sulbactam-cefoperazone plus amikacin were equally effective empiric therapy for febrile granulocytopenic cancer patients.
